#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ataxia telangiectasia Extra-osseous Ewing's sarcoma metastatic Glomerulonephritis membranous Alagille syndrome Behcet's syndrome Precursor T-lymphoblastic lymphoma/leukaemia recurrent Mycobacterium abscessus infection Small intestine leiomyosarcoma Stevens-Johnson syndrome Rhabdoid tumour Congenital aplastic anaemia HER2 mutant non-small cell lung cancer Phenylketonuria Hepatitis B Ventricular fibrillation More trials…

    Learn about Rare Diseases

    Soft tissue sarcoma Choroid melanoma – Diagnostics Hereditary angioedema – Life with Disease Carcinoid syndrome – Diagnostics Vascular malformation – Life with Disease Leukoencephalopathy – Life with Disease Progressive supranuclear palsy – Diagnostics IgA nephropathy – Diagnostics SAPHO syndrome – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mycophenolate Sodium Lamivudine Propofol ARGININE GLUTAMATE Azd8630 SC0062 Apremilast Thymalfasin Ketamine Hydrochloride A24110He Quavonlimab Acp-204 Tartrate Cariprazine Citalopram Hydrochloride Oleclumab Nazartinib Ceftazidime Pentahydrate Absk021 Hydrochloride Hydrate Povorcitinib Doxecitine More therapies…

    Learn about Your Condition

    Rectal neoplasm Pemphigoid Osteoarthritis Endometrial cancer stage III Usher's syndrome Injection site pain Eructation Vitamin D deficiency Femoral hernia Ligament sprain Haemorrhoids Cervix carcinoma stage I Overweight Herpes virus infection Myxofibrosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study on the Effects of INT230-6, Vinblastine Sulfate, and Cisplatin in Patients with Early Triple-Negative Breast Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Vinblastine Sulfate
    • Cisplatin
    France

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Ipatasertib
    • Atezolizumab
    Germany Spain

  • A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Domvanalimab
    • Zimberelimab
    Spain

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Durvalumab
    Belgium Denmark France Germany Greece Italy +2

  • Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Pembrolizumab
    Spain
Previous Page
1 … 4 5 6 7 8 … 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!